344 related articles for article (PubMed ID: 26841240)
1. Protective role of sulphoraphane against vascular complications in diabetes.
Yamagishi S; Matsui T
Pharm Biol; 2016 Oct; 54(10):2329-39. PubMed ID: 26841240
[TBL] [Abstract][Full Text] [Related]
2. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S
Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336
[TBL] [Abstract][Full Text] [Related]
3. Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products.
Maeda S; Matsui T; Ojima A; Takeuchi M; Yamagishi S
Nutr Res; 2014 Sep; 34(9):807-13. PubMed ID: 25241332
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane reduces advanced glycation end products (AGEs)-induced inflammation in endothelial cells and rat aorta.
Matsui T; Nakamura N; Ojima A; Nishino Y; Yamagishi SI
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):797-807. PubMed ID: 27212619
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
Takeuchi M; Takino J; Yamagishi S
Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
[TBL] [Abstract][Full Text] [Related]
6. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
[TBL] [Abstract][Full Text] [Related]
7. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.
Yamagishi S; Fukami K; Matsui T
Cardiovasc Diabetol; 2015 Jan; 14():2. PubMed ID: 25582643
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
[TBL] [Abstract][Full Text] [Related]
10. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
11. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
12. Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention.
Yamagishi SI
Circ J; 2019 Aug; 83(9):1822-1828. PubMed ID: 31366777
[TBL] [Abstract][Full Text] [Related]
13. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus.
Lee J; Yun JS; Ko SH
Nutrients; 2022 Jul; 14(15):. PubMed ID: 35956261
[TBL] [Abstract][Full Text] [Related]
14. Activation of RAGE-dependent endoplasmic reticulum stress associates with exacerbated postmyocardial infarction ventricular arrhythmias in diabetes.
Liu Z; Zhang Y; Pan S; Qiu C; Jia H; Wang Y; Zhu H
Am J Physiol Endocrinol Metab; 2021 Mar; 320(3):E539-E550. PubMed ID: 33459180
[TBL] [Abstract][Full Text] [Related]
15. Plasma glycation adducts and various RAGE isoforms are intricately associated with oxidative stress and inflammatory markers in type 2 diabetes patients with vascular complications.
Adeshara KA; Bangar N; Diwan AG; Tupe RS
Diabetes Metab Syndr; 2022 Mar; 16(3):102441. PubMed ID: 35247657
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of grape seed proanthocyanidin extracts on cerebral cortex of streptozotocin-induced diabetic rats through modulating AGEs/RAGE/NF-kappaB pathway.
Lu M; Xu L; Li B; Zhang W; Zhang C; Feng H; Cui X; Gao H
J Nutr Sci Vitaminol (Tokyo); 2010; 56(2):87-97. PubMed ID: 20495289
[TBL] [Abstract][Full Text] [Related]
17. Linking RAGE and Nox in diabetic micro- and macrovascular complications.
Koulis C; Watson AMD; Gray SP; Jandeleit-Dahm KA
Diabetes Metab; 2015 Sep; 41(4):272-281. PubMed ID: 26323666
[TBL] [Abstract][Full Text] [Related]
18. RAGE: a novel target for drug intervention in diabetic vascular disease.
Hudson BI; Schmidt AM
Pharm Res; 2004 Jul; 21(7):1079-86. PubMed ID: 15290845
[TBL] [Abstract][Full Text] [Related]
19. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
20. [Possible participation of advanced glycation endproducts and their receptor system in the development of diabetic vascular complications].
Yamamoto Y; Sakurai S; Watanabe T; Yonekura H; Yamamoto H
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):49-55. PubMed ID: 12617038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
